We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Affimed

News List

Affimed, Roche Explore AFM24, Tecentriq Combo contractpharma
February 04, 2021
Affimed N.V., a clinical-stage immuno-oncology company, entered a clinical research collaboration with Roche to explore the combination of Affimed’s innate cell engager (ICE) AFM24 with Roche’s PD-L1 checkpoint inhibitor atezolizumab (Tecentriq).
Affimed, NKMax America to Study EGFR-Targeted Innate Cell Engager with Natural Killer Cell Therapy americanpharmaceuticalreview
October 23, 2020
Affimed and NKMax America announced they entered into a clinical collaboration agreement to investigate the combination of AFM24, a CD16A/EGFR-targeted ICE®, with the autologous NK cell product SNK01.
Affimed shares plunge on trial death pharmatimes
October 11, 2018
Shares in German biopharma Affimed dropped near 30% after the company said it was placing a key Phase I programme of its experimental cancer immunotherapy...
Affimed's shares jump on cancer drug development deal with Roche's Genentech unit firstwordpharma
August 29, 2018
Shares in Affimed surged 140 percent after the company announced an agreement with Roche's Genentech unit to develop and commercialise NK cell engager-based immunotherapeutics to treat multiple cancers.